Abstract
Treatment of glioblastoma multiforme (GBM) has been a great challenge before medical fraternity since last century owing to a median survival of less than 15 months, despite of intensive therapy. Neurosurgeries, intense chemotherapy, advanced radiotherapy, and targeted therapies have bought some extension to the life of GBM patients. Combination and targeted therapies could bring a concrete approach to tackle the complexities of GBM treatment. Monoclonal antibodies (mAbs) have already proved their potential, owing to their high affinity and target-specificity, as a promising cancer immunotherapy. In addition, the unique optical properties of quantum dots (QDs) make them an ideal choice of nanocarrier for delivering the chemotherapeutic agents across the blood-brain barrier (BBB) and blood-tumor barrier (BTB). Present review is a concise compilation of the investigations on mAbs conjugation on the QDs surface and their anticancer efficacy against GBM. The core purpose of this review is to discuss the major challenges in the current treatment of GBM and how the mAbs-conjugated QDs have enhanced the therapeutic efficacy in the targeted immunotherapy of GBM tumor. At the end of the article, authors have briefed about the current clinical status of mAbs in GBM treatment, which would urge the researchers to explore them in conjugation with the QDs-based delivery systems. Advancements in this strategy could further open the potential avenues in the future treatments of GBM.